• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prothrombotic genetic risk factors in patients with coexisting migraine and ischemic cerebrovascular disease.

作者信息

Iniesta J A, Corral J, González-Conejero R, Rivera J, Vicente V

机构信息

General University Hospital, Murcia, Spain.

出版信息

Headache. 1999 Jul-Aug;39(7):486-9. doi: 10.1046/j.1526-4610.1999.3907486.x.

DOI:10.1046/j.1526-4610.1999.3907486.x
PMID:11279932
Abstract

The role of hemostatic elements in stroke has been clearly defined but several prothrombotic polymorphisms of hemostatic factors, important for other thromboembolic disorders, seem not to be very significant in stroke. Recently, the high prevalence of factor V Leiden in patients with stroke and a history of migraine has suggested an association between migraine and prothrombotic genetic risk factors. Stroke being a multifactorial disease, the aim of this study was to test whether prothrombotic tendencies increase the risk of stroke in patients with migraine. We determined the prevalence of four prothrombotic genetic risk factors (factor V R/Q 506, factor II 20210 G/A, decanucleotide insertion/deletion in the factor VII promoter, and the platelet HPA-1 alloantigen system) in 17 patients with coexisting ischemic cerebrovascular disease and migraine, 107 patients with ischemic cerebrovascular disease, 106 patients with migraine, and 202 control subjects. Genotyping for all polymorphisms analyzed in our study were performed after specific genomic polymerase chain reaction, and confirmed by single-strain conformation polymorphism analysis. In the group of patients with coexisting ischemic cerebrovascular disease and migraine, the prevalence of prothrombotic genotypes (factor V Leiden, 5.8%; factor II 20210 A, 0%; factor VII A1, 70.6%; and HPA-1b, 35.3%) was similar to that obtained in all other groups. We can conclude that the studied polymorphisms do not seem to be associated with the development of ischemic cerebrovascular disease in those patients with migraine.

摘要

相似文献

1
Prothrombotic genetic risk factors in patients with coexisting migraine and ischemic cerebrovascular disease.
Headache. 1999 Jul-Aug;39(7):486-9. doi: 10.1046/j.1526-4610.1999.3907486.x.
2
Migraine and prothrombotic genetic risk factors.
Cephalalgia. 1998 Jun;18(5):257-60. doi: 10.1046/j.1468-2982.1998.1805257.x.
3
Inherited prothrombotic risk factors in children with stroke, transient ischemic attack, or migraine.患有中风、短暂性脑缺血发作或偏头痛的儿童的遗传性血栓形成风险因素。
Pediatrics. 2009 Apr;123(4):e653-60. doi: 10.1542/peds.2007-3737.
4
Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases.多态性与心血管疾病凝血及生化危险因素的相关性。
Am J Cardiol. 2001 Jun 15;87(12):1361-6. doi: 10.1016/s0002-9149(01)01553-3.
5
Correlation with Platelet Parameters and Genetic Markers of Thrombophilia Panel (Factor II g.20210G>A, Factor V Leiden, MTHFR (C677T, A1298C), PAI-1, β-Fibrinogen, Factor XIIIA (V34L), Glycoprotein IIIa (L33P)) in Ischemic Strokes.血小板参数与血栓形成倾向panel(因子 II g.20210G>A、因子 V Leiden、MTHFR(C677T、A1298C)、PAI-1、β-纤维蛋白原、因子 XIII A(V34L)、糖蛋白 IIIa(L33P))的相关性与缺血性脑卒中。
Neuromolecular Med. 2016 Jun;18(2):170-6. doi: 10.1007/s12017-016-8386-x. Epub 2016 Mar 7.
6
Role of factor XIII Val 34 Leu polymorphism in patients with migraine.凝血因子XIII Val 34 Leu基因多态性在偏头痛患者中的作用
Cephalalgia. 2001 Oct;21(8):837-41. doi: 10.1046/j.0333-1024.2001.00273.x.
7
[Prothrombotic disturbances in children after ischemic stroke].[缺血性中风后儿童的血栓前状态紊乱]
Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(12 Suppl 2):18-24.
8
The role of classic risk factors and prothrombotic factor gene mutations in ischemic stroke risk development in young and middle-aged individuals.经典危险因素和血栓形成前体因子基因突变在中青年个体缺血性卒中风险发展中的作用。
J Stroke Cerebrovasc Dis. 2014 Mar;23(3):e171-6. doi: 10.1016/j.jstrokecerebrovasdis.2013.09.025. Epub 2013 Nov 1.
9
Association of Polymorphisms in Coagulation Factor Genes and Enzymes of Homocysteine Metabolism With Arterial Ischemic Stroke in Children.凝血因子基因多态性及同型半胱氨酸代谢酶与儿童动脉缺血性卒中的关联
Clin Appl Thromb Hemost. 2017 Nov;23(8):1042-1051. doi: 10.1177/1076029616672584. Epub 2016 Oct 18.
10
Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage.凝血因子多态性会改变原发性颅内出血的风险。
Blood. 2001 May 15;97(10):2979-82. doi: 10.1182/blood.v97.10.2979.

引用本文的文献

1
Association of Glycoprotein IIIa PlA1/A2 Polymorphism with Risk of Stroke: Updated Meta-Analysis.糖蛋白IIIa PlA1/A2多态性与中风风险的关联:更新的荟萃分析。
Curr Issues Mol Biol. 2024 May 28;46(6):5364-5378. doi: 10.3390/cimb46060321.
2
Migraine and vascular disease biomarkers: A population-based case-control study.偏头痛和血管疾病生物标志物:基于人群的病例对照研究。
Cephalalgia. 2018 Mar;38(3):511-518. doi: 10.1177/0333102417698936. Epub 2017 Mar 15.
3
Thrombophilic disorders in migraine.偏头痛中的血栓形成倾向疾病
Front Neurol. 2014 Jul 10;5:120. doi: 10.3389/fneur.2014.00120. eCollection 2014.
4
The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis.糖蛋白IIIa的PlA1/A2多态性作为中风的危险因素:一项系统评价和荟萃分析。
PLoS One. 2014 Jul 2;9(7):e100239. doi: 10.1371/journal.pone.0100239. eCollection 2014.
5
Large-scale meta-analysis of genetic studies in ischemic stroke: Five genes involving 152,797 individuals.缺血性中风基因研究的大规模荟萃分析:涉及152797人的五个基因。
Indian J Hum Genet. 2011 Sep;17(3):212-7. doi: 10.4103/0971-6866.92105.
6
A candidate gene association study of 77 polymorphisms in migraine.一项关于偏头痛中77种多态性的候选基因关联研究。
J Pain. 2009 Jul;10(7):759-66. doi: 10.1016/j.jpain.2009.01.326.
7
Antithrombotic therapy for stroke in young adults.年轻成年人中风的抗栓治疗
J Thromb Thrombolysis. 2005 Oct;20(2):127-32. doi: 10.1007/s11239-005-3206-4.
8
The risk of stroke in patients with migraine and implications for migraine management.偏头痛患者的中风风险及其对偏头痛管理的影响。
CNS Drugs. 2005;19(8):683-92. doi: 10.2165/00023210-200519080-00004.